litlas
Log inCreate account

Shu Li

Active 1968–2026

Also published as
Shu, Li
869
Papers
58,884
Citations
121
h-index
628
i10-index

Citations

Citations per year for Shu Li1958: 3 citations1960: 1 citations1969: 2 citations1970: 4 citations1971: 3 citations1972: 3 citations1973: 5 citations1974: 2 citations1976: 1 citations1978: 2 citations1979: 1 citations1982: 2 citations1984: 1 citations1987: 1 citations1988: 2 citations1991: 6 citations1992: 3 citations1993: 3 citations1994: 6 citations1995: 4 citations1996: 11 citations1997: 6 citations1998: 13 citations1999: 11 citations2000: 23 citations2001: 27 citations2002: 70 citations2003: 86 citations2004: 99 citations2005: 140 citations2006: 150 citations2007: 186 citations2008: 257 citations2009: 354 citations2010: 425 citations2011: 547 citations2012: 503 citations2013: 542 citations2014: 529 citations2015: 484 citations2016: 469 citations2017: 606 citations2018: 637 citations2019: 1,783 citations2020: 2,159 citations2021: 2,350 citations2022: 1,974 citations2023: 1,778 citations2024: 2,775 citations2025: 1,842 citations2026: 137 citations1959: no citations, so this year is not shown1961–1968: no citations, so these years are not shown1975: no citations, so this year is not shown1977: no citations, so this year is not shown1980–1981: no citations, so these years are not shown1983: no citations, so this year is not shown1985–1986: no citations, so these years are not shown1989–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 6,425 citing papers, 26.1% of this breakdownUnited States: 4,537 citing papers, 18.4% of this breakdownGermany: 1,549 citing papers, 6.3% of this breakdownUnited Kingdom: 1,429 citing papers, 5.8% of this breakdownCanada: 965 citing papers, 3.9% of this breakdownItaly: 754 citing papers, 3.1% of this breakdownFrance: 580 citing papers, 2.3% of this breakdownAustralia: 578 citing papers, 2.3% of this breakdownIndia: 485 citing papers, 2% of this breakdownNetherlands: 473 citing papers, 1.9% of this breakdownJapan: 465 citing papers, 1.9% of this breakdownSwitzerland: 451 citing papers, 1.8% of this breakdown
0%26.1%Other 24.2%

Institutions

Fields

  • Medicine26.1%
  • Immunology and Microbiology14.9%
  • Biochemistry, Genetics and Molecular Biology14.1%
  • Neuroscience11.6%
  • Computer Science8.1%
  • Engineering6.1%
  • Other19.1%

Topics

  • Psoriasis: Treatment and Pathogenesis2.9%
  • interferon and immune responses2.5%
  • Neural and Behavioral Psychology Studies1.9%
  • Spondyloarthritis Studies and Treatments1.6%
  • Functional Brain Connectivity Studies1.6%
  • Dermatology and Skin Diseases1.4%
  • Other88.1%

Coauthors

All papers

Open in search
  1. Major depressive disorder: hypothesis, mechanism, prevention and treatment

    Authors: Lulu Cui, Shu Li, Siman Wang, Xiafang Wu, Yingyu Liu, Weiyang Yu, Yijun Wang, Yong Tang, Maosheng Xia, Baoman Li - Signal Transduction and Targeted Therapy 2024 cited by 905

  2. PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation

    Authors: Qisheng Lin, Shu Li, Na Jiang, Xinghua Shao, Minfang Zhang, Haijiao Jin, Zhen Zhang, Jianxiao Shen, Yijun Zhou, Wenyan Zhou, Leyi Gu, Renhua Lu, Zhaohui Ni - Redox Biology 2019 cited by 616

  3. The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation

    Authors: Bo Zhong, Yan Yang, Shu Li, Yanyi Wang, Ying Li, Feici Diao, Cao‐Qi Lei, Xiao He, Lu Zhang, Po Tien, Hong-Bing Shu - Immunity 2008 cited by 1,493

  4. Mitophagy alleviates cisplatin-induced renal tubular epithelial cell ferroptosis through ROS/HO-1/GPX4 axis

    Authors: Qisheng Lin, Shu Li, Haijiao Jin, Hong Cai, Xuying Zhu, Yuanting Yang, Jingkui Wu, Chaojun Qi, Xinghua Shao, Jialin Li, Kaiqi Zhang, Wenyan Zhou, Minfang Zhang, Jiayi Cheng, Leyi Gu, Shan Mou, Zhaohui Ni - International Journal of Biological Sciences 2023 cited by 222

  5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Authors: Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, B. Randazzo, Yasmine Wasfi, Yaung‐Kaung Shen, Shu Li, Alexa B. Kimball - Journal of the American Academy of Dermatology 2017 cited by 860

  6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

    Authors: Kristian Reich, April W. Armstrong, Peter Foley, Michael Song, Yasmine Wasfi, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Kenneth B. Gordon - Journal of the American Academy of Dermatology 2017 cited by 731

  7. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

    Authors: Kristian Reich, April W. Armstrong, Richard G. Langley, Susan Flavin, B. Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt - The Lancet 2019 cited by 376

  8. Co-GCN for Multi-View Semi-Supervised Learning

    Authors: Shu Li, Wen-Tao Li, Wei Wang - AAAI Conference on Artificial Intelligence 2020 cited by 91

  9. A K-Anonymity Based Schema for Location Privacy Preservation

    Authors: Fan Fei, Shu Li, Haipeng Dai, Chunhua Hu, Wanchun Dou, Qiang Ni - IEEE Transactions on Sustainable Computing, IEEE Trans. Sustain. Comput. 2017 cited by 151

  10. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Authors: Craig L. Leonardi, Alexa B. Kimball, Kim Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T. Dooley, Kenneth B. Gordon - The Lancet 2008 cited by 1,865

  11. Therapeutic Targeting of the Staphylococcus aureus Accessory Gene Regulator (agr) System

    Authors: Li Tan, Si Rui Li, Si Rui Li, Bei Jiang, Xiao Mei Hu, Shu Li, Shu Li - Frontiers in Microbiology 2018 cited by 231

  12. Structural basis of CXC chemokine receptor 2 activation and signalling

    Authors: Kaiwen Liu, Lijie Wu, Shuguang Yuan, Meng Wu, Yueming Xu, Qianqian Sun, Shu Li, Suwen Zhao, Tian Hua, Zhi‐Jie Liu - Nature 2020 cited by 238

  13. Association of Ultraprocessed Food Consumption With Risk of Dementia

    Authors: Huiping Li, Shu Li, Hongxi Yang, Yuan Zhang, Shunming Zhang, Yue Ma, Yabing Hou, Xinyu Zhang, Kaijun Niu, Yan Borné, Yaogang Wang - Neurology 2022 cited by 105

  14. Consumption of coffee and tea and risk of developing stroke, dementia, and poststroke dementia: A cohort study in the UK Biobank

    Authors: Yuan Zhang, Hongxi Yang, Shu Li, Weidong Li, Yaogang Wang - PLoS Medicine 2021 cited by 197

  15. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

    Authors: Kim Papp, Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich - The Lancet 2008 cited by 1,350

  16. Polystyrene nanoplastics deteriorate LPS-modulated duodenal permeability and inflammation in mice via ROS drived-NF-κB/NLRP3 pathway

    Authors: Yujiao He, Zhe Li, Tong Xu, Dongliu Luo, Qianru Chi, Yiming Zhang, Shu Li - Chemosphere 2022 cited by 170

  17. Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

    Authors: Jingjing Shen, Huiqin Gao, Linfu Chen, Yutong Jiang, Shu Li, Yu Chao, Nanhui Liu, Yufei Wang, Ting Wei, Yan Liu, Jipeng Li, Muchao Chen, Jiafei Zhu, Juan Liang, Zhou Xiao-yu, Xiaofeng Zhang, Ping Gu, Qian Chen, Zhuang Liu - Science Advances 2023 cited by 84

  18. Aging cognition: from neuromodulation to representation

    Authors: Shu Li, Ulman Lindenberger, Sverker Sikström - Trends in Cognitive Sciences 2001 cited by 924

  19. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

    Authors: Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb, L. Puig, Proton Rahman, Christopher T. Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M. Mendelsohn, Mittie K. Doyle - The Lancet 2013 cited by 798

  20. Effects of school-based high-intensity interval training on body composition, cardiorespiratory fitness and cardiometabolic markers in adolescent boys with obesity: a randomized controlled trial

    Authors: Meng Cao, Yucheng Tang, Shu Li, Yu Zou - BMC Pediatrics 2022 cited by 115

  21. Antiviral PROTACs: Opportunity borne with challenge

    Authors: Jinsen Liang, Yihe Wu, Ke Lan, Chune Dong, Shuwen Wu, Shu Li, Hai‐Bing Zhou - Cell Insight 2023 cited by 65

  22. An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis

    Authors: Robert Bissonnette, Andreas Pinter, Laura K. Ferris, Sascha Gerdes, Phoebe Rich, Ronald Vender, Megan Miller, Yaung‐Kaung Shen, Arun Kannan, Shu Li, Cynthia Marie Carver DeKlotz, Kim Papp - New England Journal of Medicine 2024 cited by 78

  23. Nanozyme‐Enabled Biomedical Diagnosis: Advances, Trends, and Challenges

    Authors: Qingzhen Tian, Shu Li, Zheng Tang, Ziyu Zhang, Dan Du, Xiao Zhang, Xiangheng Niu, Yuehe Lin - Advanced Healthcare Materials 2024 cited by 110

  24. Comparisons of heuristic, general statistical and machine learning models for landslide susceptibility prediction and mapping

    Authors: Faming Huang, Zhongshan Cao, Jianfei Guo, Shui‐Hua Jiang, Shu Li, Zizheng Guo - CATENA 2020 cited by 476